0837 GMT - GSK needs to convince investors of a sustainable vaccine outlook after it cut the 2025 sales target of its jabs, Shore Capital analyst Sean Conroy says. The British pharma company now guides for a low single-digit decrease in vaccine sales for this year after a slowdown in the U.S., notably for its RSV shot Arexvy that missed consensus estimates by 18%, the analyst says. "Some tangible evidence the transient challenges facing Shingrix [shingles vaccine] and Arexvy can be navigated will likely be needed to reinstill the conviction in management's longer-term expectations for these," he says in a note. Shares are up 5.7% at 1,458.50 pence. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 03:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。